ACA
RAPT

Avoro Capital Advisors’s RAPT Therapeutics RAPT Stock Holding History

Avoro Capital Advisors’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-71,875
Closed -$18.5M – 49
2020
Q3 		$18.5M Buy
+71,875
New +$16M 0.26% 36

Other funds holding RAPT

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
KXA
KPCB XV Associates Menlo Park, California $35.8M AUM 57.59% 1-Year Est. Return
PM
Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ROTUOC
Regents of the University of California Oakland, California $3.01B AUM 11.91% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

Avoro Capital Advisors's RAPT Position: Q4 2020 in Review

Avoro Capital Advisors sold out of RAPT Therapeutics (RAPT) in Q4 2020, closing a stake of 71,875 shares — an estimated $18.5M sold.

Avoro Capital Advisors first reported a position in RAPT in Q3 2020 and held it in 1 quarter. The position peaked at $18.5M in Q3 2020. 81 funds tracked by Wall St. Rank hold RAPT as of Q4 2020.

  • Avoro Capital Advisors reported no remaining RAPT Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Avoro Capital Advisors sold 71,875 RAPT Therapeutics shares in Q4 2020, an estimated $18.5M.
  • Avoro Capital Advisors first reported a position in RAPT Therapeutics in Q3 2020 and held it in 1 quarter.
  • Avoro Capital Advisors's RAPT Therapeutics position peaked at $18.5M in Q3 2020.
  • 81 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q4 2020.

Based on Avoro Capital Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.